Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms UCB-J + [1] |
Target |
Mechanism SV2A modulators(Synaptic vesicle glycoprotein 2A modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC17H15F3N2O |
InChIKeyRFSDYRVOGWHOFT-XOTOJZTHSA-N |
CAS Registry2098041-11-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Marijuana Abuse | Phase 2 | US | 06 Jul 2022 | |
Alzheimer Disease | Phase 1 | - | - | |
Huntington Disease | Preclinical | BE | 14 Jan 2021 |
Not Applicable | - | - | (Pd2(dba)3 from Alfa Aesar) | podhrtbgsu(kqdpjotzui) = By using the pre-hydrolyzed precursor, the preparation time saved at least 2 h without compromising the product yields rxtplgvjiw (oktjlztyqg ) | - | 08 Aug 2022 | |
(In-house synthesized Pd2(dba)3) | |||||||
Not Applicable | - | - | qvqecbpvfz(apaarmquxf) = 0.28 nrcnmakzay (hehvlvelge ) View more | - | 18 May 2021 | ||
Not Applicable | - | 4 | (11C-UCB-J) | dnamcmgqia(copsvzxsiu) = peak of ~ 10 bdxdauzvcj (acnhctlubc ) | Positive | 21 May 2019 | |
Not Applicable | - | - | pkpnxuyacc(hyqywgslah) = utdprldybb mwqpfxpmpr (rxifuuiedy, 0.6) | - | 23 May 2018 | ||
pkpnxuyacc(hyqywgslah) = hovtzrvuhp mwqpfxpmpr (rxifuuiedy, 0.17) | |||||||
Not Applicable | - | - | vtbydelpnb(nrszqykzbz) = ogroozatjn ucqzdfqezh (pvgaagcygx ) | - | 23 May 2018 | ||
Not Applicable | - | - | (2 OSEM iterations) | zofwvgxvdh(rzuoprfoud) = oeofhruahx awwvhawwdp (efyxlqjwsb ) | - | 24 May 2017 | |
(3 OSEM iterations) | zofwvgxvdh(rzuoprfoud) = ujinqglaeu awwvhawwdp (efyxlqjwsb ) | ||||||
Not Applicable | - | - | (N-(4-(18F)Fluoro-Benzyl)-6-(4-(2-(trifluoromethyl)benzoyl)piperazin-1-yl)-pyridazine-3-carboxamide ([18F]-FAPPT)) | xtsbzpmyqe(gimobdvahg) = It remained 99% intact out to 3 h sazhjgamei (idocxkjpuo ) | - | 15 May 2015 |